Cost of lost productivity in inflammatory arthritis and osteoarthritis in the year before and after diagnosis: An inception cohort study
International Journal of Rheumatic Diseases · 2024
DOI: 10.1111/1756-185x.15252 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Ling Xiang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore. Hauptthemen laut MEDLINE: Absenteeism, Osteoarthritis, Presenteeism, Efficiency. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aim
Existing studies on the cost of inflammatory arthritis (IA) and osteoarthritis (OA) are often cross‐sectional and/or involve patients with various disease durations, thus not providing a comprehensive perspective on the cost of illness from the time of diagnosis. In this study, we therefore assessed the cost of lost productivity in an inception cohort of patients with IA and OA in the year before and after diagnosis.
Methods
Employment status, monthly income, days absent from work, and presenteeism were collected at diagnosis and 1 year later to estimate the annual costs of unemployment, absenteeism, and presenteeism using human capital approach. Non‐parametric bootstrapping was performed to account for the uncertainty of the estimated costs.
Results
Compared to patients with OA ( n = 64), patients with IA ( n = 102, including 48 rheumatoid arthritis, 19 spondyloarthritis, 23 psoriatic arthritis, and 12 seronegative IA patients) were younger (mean age: 52.3 vs. 59.5 years) with a greater proportion receiving treatment (99.0% vs. 67.2%) and a greater decrease in presenteeism score (median: 15% vs 10%) 1 year after diagnosis. Annual costs of absenteeism and presenteeism were lower in patients with IA than those with OA both in the year before (USD566 vs. USD733 and USD8,472 vs. USD10,684, respectively) and after diagnosis (USD636 vs. USD1,035 and USD6,866 vs. USD9,362, respectively).
Conclusion
Both IA and OA impose substantial cost of lost productivity in the year before and after diagnosis. The greater improvement in productivity seen in patients with IA suggests that treatment for IA improves work productivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore.
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore.
- Duke-NUS Medical School, Singapore, Singapore.
- Department of Occupational and Environmental Medicine, Singapore General Hospital, Singapore, Singapore.
- Biostatistics, Singapore Clinical Research Institute, Singapore, Singapore.
ORCID-Profile: Ling Xiang, Warren Fong, Julian Thumboo
Zitieren
APA
Xiang, L., Graves, N., Low, A. H. L., Leung, Y. Y., Fong, W., Gan, W. H., Gandhi, M., & Thumboo, J. (2024). Cost of lost productivity in inflammatory arthritis and osteoarthritis in the year before and after diagnosis: An inception cohort study. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.15252
Vancouver
Xiang L, Graves N, Low AHL, Leung YY, Fong W, Gan WH, et al. Cost of lost productivity in inflammatory arthritis and osteoarthritis in the year before and after diagnosis: An inception cohort study. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.15252
BibTeX
@article{Xiang2024,
author = {Xiang, Ling and Graves, Nicholas and Low, Andrea H L and Leung, Ying-Ying and Fong, Warren and Gan, Wee-Hoe and Gandhi, Mihir and Thumboo, Julian},
title = {Cost of lost productivity in inflammatory arthritis and osteoarthritis in the year before and after diagnosis: An inception cohort study},
journal = {International Journal of Rheumatic Diseases},
year = {2024},
doi = {10.1111/1756-185x.15252}
}
EUVIMED